Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Psychogenics and Emyria are collaborating to examine MDMA-inspired compounds

By Brian Buntz | October 12, 2022

Emyria/PychogenicsCNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage biotech Emyria Ltd to study five novel MDMA-inspired drug candidates for severe neuropsychiatric conditions.

Emyria and its partner, the University of Western Australia, will initially screen five novel MDMA analogs with PsychoGenic’s computer vision and AI-based testing platform. The organizations expect the alliance to inform and predict the clinical effects of new drug compounds, including Emyria’s MDMA-inspired library.

PsychoGenics will compare the MDMA-based compounds to known reference drug libraries.

The companies anticipate that the alliance will facilitate the accelerated development of the MDMA-inspired library that holds potential for conditions ranging from Parkinson’s disease to post-traumatic stress disorder (PTSD).

PsychoGenics and Emyria will work collaboratively before exploring drug discovery and commercialization partnership models.

Inspired by MAPS’ research

Mark Varney

Mark Varney, PhD [Image courtesy of PsychoGenics]

The Multidisciplinary Association for Psychedelic Studies (MAPS) helped set the stage for the legitimization of the street drug MDMA with a Phase 3 clinical study of MDMA in PTSD patients. The study found that MDMA “significantly attenuated PTSD symptomology.”

In 2017, the FDA granted breakthrough therapy designation for MDMA-assisted psychotherapy for PTSD after reviewing data from a Phase 2 study.

PTSD is “a notoriously difficult condition to treat,” said Mark Varney, PsychoGenics’ chief scientific officer. The positive data involving the use of MDMA in PTSD has “fostered an interest in using MDMA or MDMA analogs for the treatment of PTSD or perhaps other disorders,” Varney said.

The exploratory partnership with Emyria will ultimately investigate the potential of roughly 200 MDMA analogs.

Bringing Emyria’s analogs together with PsychoGenics’ Smart Cube screening platform will “give us a potential competitive advantage in the development of next-generation MDMA analogs,” Varney said.

Overcoming MDMA drawbacks

MDMA typically has a duration of action ranging from four to six hours. That relatively long window can require significant staffing to care for patients who receive the drug along with psychotherapy.

Patients typically come in for a therapy session without the drug. They then have three sessions with the drug treatment and then have a follow-up visit. “During the drug treatment sessions, the patients have to be there, eight to 12 hours or even sometimes overnight, because of the fairly long-lasting effects of the drug,” Varney said.

Shortening the duration of action for MDMA could enable clinicians to potentially offer the drug’s therapeutic benefit in a shorter time window.

The hunt is on for MDMA analogs with similar properties but with a shorter duration of effect.

Another drawback of MDMA is that it stimulates the serotonin 5-HT2b receptor, which could potentially cause cardiac valve defects with long-term use. One small study published in The American Journal of Cardiology found abnormal echocardiographic functionality in individuals who had taken MDMA.

Classic psychedelics such as LSD and psilocybin also have 5-HT2b receptor affinities. That fact has inspired several companies to generate molecules inspired by MDMA or classic psychedelics that have “more selective pharmacology to avoid binding, for example, to the 5-HT2b receptor,” Varney said.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: Emyria, PsychoGenics
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE